Menu

Refine search:

Filter by date

Filter results

First Previous 1 Next Last 
 
Add to print list
in drug discovery in recent years, with a number of UK-based companies leading the way in the field e.g. BenevolentAI
of AI/ML). BenevolentAI has identified that baricitinib, which has been approved for rheumatoid arthriti
Add to print list
discovery. There are many examples including BenevolentAI, Healx and GTN Ltd (Generative Tensorial Networks
Add to print list
Arm BBC BT Dyson Evolyst System C Healthcare Thales Others £100m BenevolentAI AI
Add to print list
databases and proprietary, curated data in a similar way to BenevolentAI (see BenevolentAI raises $115m
Add to print list
Channel 4 Arqiva Growth £125m BenevolentAI AI-based drug discovery software Woodford Investment Man
Add to print list
for the UK to lead the way in artificial intelligence was also highlighted. Mentioning BenevolentAI, Babylon Health, Touch Surgery and DeepMind, Hancock
Add to print list
like they are securing high levels of funding, BenevolentAI with £115m funding during
Add to print list
is a prime and active area for AI/machine learning: BenevolentAI raises $115m to scale-up drug discovery being one recent
Add to print list
AI healthcare business BenevolentAI has appointed Baroness Joanna Shields as its new Group CEO
at Decru/NetApp, VP at RealNetworks, CEO at Veon and VP at EFI. This is a sound appointment for BenevolentAI
in growing bu
Add to print list
BenevolentAI, the UK start-up applying artificial intelligence (AI) to develop new medicines, has
-based, as well as existing investors including Woodford Investment Management. BenevolentAI has now raised in excess of $200m si
 
First Previous 1 Next Last